OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in pharmacology
2014;5 102.

The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries.

Johan Lundkvist, Magnus M Halldin, Johan Sandin, Gunnar Nordvall, Pontus Forsell, Samuel Svensson, Liselotte Jansson, Gunilla Johansson, Bengt Winblad, Jonas Ekstrand
Author Information
  1. Johan Lundkvist: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
  2. Magnus M Halldin: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
  3. Johan Sandin: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
  4. Gunnar Nordvall: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
  5. Pontus Forsell: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
  6. Samuel Svensson: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
  7. Liselotte Jansson: Alzheimerfonden, Frösundavik Solna, Sweden.
  8. Gunilla Johansson: Center for Alzheimer Research at Karolinska Institutet and Swedish Brain Power Novum, Huddinge, Sweden.
  9. Bengt Winblad: Center for Alzheimer Research at Karolinska Institutet and Swedish Brain Power Novum, Huddinge, Sweden.
  10. Jonas Ekstrand: AlzeCure Foundation, Karolinska Institutet Science Park Novum Huddinge, Sweden.
PMID: 24847271 DOI: 10.3389/fphar.2014.00102

Abstract

Alzheimer's Disease (AD) is the most common form of dementia, affecting approximately 36 million people worldwide. To date there is no preventive or curative treatment available for AD, and in absence of major progress in therapeutic development, AD manifests a concrete socioeconomic threat. The awareness of the growing problem of AD is increasing, exemplified by the recent G8 dementia Summit, a meeting held in order to set the stage and steer the compass for the future. Simultaneously, and paradoxically, we have seen key players in the pharmaceutical industry that have recently closed or significantly decreased their R&D spending on AD and other CNS disorders. Given the pressing need for new treatments in this area, other actors need to step-in and enter this drug discovery arena complementing the industrial efforts, in order to turn biological and technological progress into novel therapeutics. In this article, we present an example of a novel drug discovery initiative that in a non-profit setting, aims to integrate with both preclinical and clinical academic groups and pharmaceutical industry to explore the therapeutic potential of new concepts in patients, using novel biology, state of the art technologies and rapid concept testing.

Keywords

Alzheimer’s disease collaborative research drug discovery and development non-profit pharmaceutical technology

References

  1. Chem Rev. 2012 Oct 10;112(10):5193-239 [PMID: 22793492]
  2. Lancet Neurol. 2010 Jul;9(7):702-16 [PMID: 20610346]
  3. Neuron. 2006 Oct 5;52(1):3-13 [PMID: 17015223]
  4. Nat Rev Drug Discov. 2012 Mar 01;11(3):191-200 [PMID: 22378269]
  5. Expert Opin Investig Drugs. 2012 Sep;21(9):1267-308 [PMID: 22741814]
  6. Dement Geriatr Cogn Disord. 2012;33(1):18-28 [PMID: 22377499]
  7. Lancet Neurol. 2011 Jul;10(7):667-70 [PMID: 21683932]
  8. J Clin Invest. 2006 Nov;116(11):2837-42 [PMID: 17080187]
  9. N Engl J Med. 2014 Jan 23;370(4):322-33 [PMID: 24450891]
  10. J Intern Med. 2014 Mar;275(3):251-83 [PMID: 24605808]
  11. Alzheimers Dement. 2011 May;7(3):280-92 [PMID: 21514248]
  12. Nat Rev Drug Discov. 2007 Feb;6(2):107-8 [PMID: 17342862]
  13. J Alzheimers Dis. 2006;9(3 Suppl):5-13 [PMID: 17004361]
  14. Exp Neurol. 2008 Jan;209(1):82-8 [PMID: 17963752]
  15. Alzheimers Dement. 2013 Mar;9(2):208-45 [PMID: 23507120]
  16. Natl Vital Stat Rep. 2012 Aug 28;60(8):1-22 [PMID: 24979970]
  17. Nat Rev Drug Discov. 2013 Nov;12(11):811-2 [PMID: 24172316]
  18. Nat Rev Drug Discov. 2009 Dec;8(12):959-68 [PMID: 19949401]
  19. Nature. 2011 Dec 06;480(7376):161-2 [PMID: 22158218]
  20. Nat Rev Drug Discov. 2004 Aug;3(8):711-5 [PMID: 15286737]
  21. Alzheimers Dement. 2013 Jan;9(1):39-49 [PMID: 23164548]
  22. Curr Neuropharmacol. 2014 Jan;12(1):2-36 [PMID: 24533013]
  23. Nat Rev Drug Discov. 2012 Nov;11(11):833-46 [PMID: 23123941]
  24. Nat Rev Drug Discov. 2010 Mar;9(3):203-14 [PMID: 20168317]
  25. Neurol Sci. 2013 Jun;34(6):831-9 [PMID: 23392897]
  26. Adv Pharmacol. 2012;64:213-71 [PMID: 22840749]
  27. N Engl J Med. 2014 Jan 23;370(4):311-21 [PMID: 24450890]
  28. Neuropsychopharmacology. 2012 Jan;37(1):261-77 [PMID: 21937983]
  29. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137-47 [PMID: 10071091]
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0ADpharmaceuticaldrugdiscoverynovelAlzheimer'sDiseaseprogresstherapeuticdevelopmentorderfutureindustryneednewnon-profitacademicpotentialcommonformdementiaaffectingapproximately36millionpeopleworldwidedatepreventivecurativetreatmentavailableabsencemajormanifestsconcretesocioeconomicthreatawarenessgrowingproblemincreasingexemplifiedrecentG8DementiaSummitmeetingheldsetstagesteercompassSimultaneouslyparadoxicallyseenkeyplayersrecentlyclosedsignificantlydecreasedR&DspendingCNSdisordersGivenpressingtreatmentsareaactorsstep-inenterarenacomplementingindustrialeffortsturnbiologicaltechnologicaltherapeuticsarticlepresentexampleinitiativesettingaimsintegratepreclinicalclinicalgroupsexploreconceptspatientsusingbiologystatearttechnologiesrapidconcepttestingbattle-beginningUnleashingdiscoveriesAlzheimer’sdiseasecollaborativeresearchtechnology

Similar Articles

Cited By